Xarelto® (Rivaroxaban) is a popular blood-thinning drug manufactured by Bayer. Since it received FDA approval in 2011, more and more people have been caused to suffer fatal internal bleeding, strokes and blood clots. Xarelto® was created as an alternative to warfarin (Coumadin®), which is prescribed to prevent blood clots in patients suffering from atrial fibrillation (arrhythmia of the heart), deep vein thrombosis, pulmonary embolism, stroke, and patients who have recently undergone knee or hip replacement surgery.
Xarelto® was pushed to the market as an easier alternative to warfarin, advertised as a ‘once-a-day’ blood thinner that does not require regular testing. However, in the rush to get it into the hands of patients, resulting Billions of dollars in U.S. sales, the health of its consumers took a back seat, resulting in many fatalities and serious injuries. Unfortunately, many of the injuries resulting from the consumption of Xarelto® could have been avoided had the manufacturers of this drug simply warned physicians and patients to receive annual blood testing, in order to identify those who were high-risk to suffer serious negative side effects.
If you or someone you know has taken Xarelto® and have been caused to suffer serious negative side effects (internal bleeding, strokes and blood clots), there is a time limit on how long you have to pursue your case called the Statute of Limitations. The Statute of Limitations is different in each state. Therefore, if you or someone you know has suffered the serious negative side effects caused by taking Xarelto, have them contact a Xarelto Attorney at Sweeney Merrigan Law to have their case evaluated before it’s too late.
Xarelto (rivaroxaban) quickly became the blood-thinner of choice for patients looking to prevent the formation of blood clots after its FDA approval in 2011. Xarelto was created by Janssen, a division of Johnson & Johnson, as a more consumer-friendly version of Coumadin. This new anticoagulant was marketed especially toward patients suffering from heart arrhythmia, deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke, with the promise of preventing blood clots as well as competitor brands.
However, what older brands provided that Xarelto lacked was the all-important existence of an emergency antidote to the risk of internal bleeding. Internal bleeding is a risk factor of any blood thinner, and other medications used this knowledge to create a safety net for their customers. Because of pressure to get Xarelto on the market, the manufacturers skipped this step – a fatal decision that’s since resulted in hundreds of people suffering from unstoppable internal bleeding, along with several other health defects.
Xarelto was the first blood thinner on the market that advertised once-daily dosages, leading to doctors everywhere immediately jumping on board to suggest to patients that they switch from other blood thinners to the newer, simpler Xarelto. The apparent decreased risk of brain hemorrhages and other bleeding events that traditionally led to patients needing routine check-ups encouraged people everywhere to try Xarelto.
Another bonus associated with Xarelto was the fact that the FDA approved its use by patients who had undergone hip or knee replacement surgeries, suggested to prevent the occurrence of PE and DVT.
With the upsurge in people switching to Xarelto for their daily anticoagulant, there was a relative increase in people experiencing serious health concerns relating to the medication. Only months after Xarelto hit the market, patients began citing health complaints, both minor and life threatening.
Minor side effects include tendency to bruise, small cuts bleeding more, and muscle pain. More serious effects have included:
Xarelto also cannot be flushed out of the system via dialysis; it is only flushed out naturally. Allowing uncontrolled bleeding to continue for any period of time can interrupt the function of major organs such as the lungs, brain, and kidneys. It can also result in the formation of pools of blood within the body, which can lead to various other serious health risks.
Even though Xarelto was originally marketed to show its apparent lack of risk of hemorrhaging, this is precisely the problem that most patients have encountered while on the drug. Unfortunately, the dangerous side effects of taking Xarelto were not made known by the company prior to it becoming available. All of the serious health complications associated with Xarelto could have been prevented had Janssen properly tested the drug as they should have.
There are legal options for compensation for those who have taken Xarelto and suffered from any adverse effects, especially life-threatening symptoms such as irreversible bleeding. A number of lawsuits have already been filed against Johnson & Johnson in the hopes that the company will recall the product and take it off the market.
The experienced attorneys at Sweeney Merrigan Law can effectively address your individual Xarelto-related situation and will use methods of detailed case evaluation, one-on-one consultation, and expert legal advice pertaining to the laws of healthcare.